InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,307.29
(
0.75%
)
US TECH 100
18,342.00
(
1.08%
)
Dow Jones
39,184.98
(
0.31%
)
Brent Oil
81.85
(
0.66%
)
Bitcoin
68,105.18
(
0.27%
)
Post# of 251930
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119686
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 201591

Sunday, 12/04/2016 11:54:34 AM

Sunday, December 04, 2016 11:54:34 AM

Post# of 251930
SGEN drops Adcetris program in first-line DLBCL:

http://finance.yahoo.com/news/seattle-genetics-presents-data-phase-180000349.html

…based on prioritization of our pipeline, we are discontinuing this [phase-2] trial and have decided not to pursue a registrational pathway for ADCETRIS in frontline DLBCL. We continue to evaluate ADCETRIS in the treatment of relapsed or refractory DLBCL through an ongoing randomized phase 2 trial, as well as more broadly for other CD30-expressing lymphomas, including the ECHELON-1 and ECHELON-2 phase 3 trials in frontline classical Hodgkin lymphoma and frontline mature T-cell lymphoma, respectively.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up